Pivotal bioVenture Increases Stake in Trevi Therapeutics Amid Significant Share Price Growth

According to an SEC filing from May 14, 2026, Pivotal bioVenture Partners Investment Advisor increased its stake in Trevi Therapeutics (TRVI) by acquiring 296,944 shares for $3.32 million during the first quarter of 2026. The fund now holds a total position valued at $18.54 million or 6.6% of reportable AUM as of March 31, 2026.

By Sara Appino · Motley Fool · June 3, 2026, 13:44 UTC

Tickers: $TRVI

Topics: institutional investment SEC filing Trevi Therapeutics

Read the full article at Motley Fool

More World news

Blackbaud Reports Third Quarter Revenue Growth and Strategic AI Integration Motley Fool · November 12, 2026, 17:53 UTC
Sprott Physical Copper Trust Reports Significant Increase in Q3 Net Income Seeking Alpha · November 12, 2026, 17:51 UTC
Federal Reserve to Designate October 2027 Meeting as Non-Voting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC